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Vicinal disulfide constrained cyclic peptidomimetics: a turn mimetic scaffold targeting the 
norepinephrine transporter  
Andreas Brust*, Ching-I A Wang, Norelle L Daly, Joe Kennerly, Mahsa Sadeghi, Macdonald J Christie, Richard J Lewis, 
Mehdi Mobli* and Paul F Alewood* 
The design of peptidomimetics[1] of peptide-protein or 
protein-protein interactions needs to take into consideration 
the specific amino acid interactions between the ligand and 
its protein receptor.[2] Peptide turns play an essential role in 
many recognition events,[2] including receptor recognition in 
the most abundant receptor class, GPCRs,[3] with many 
bioactive peptides adopting - or - turn conformations.[3] 
Peptide turn mimetic strategies range from local peptide 
amino acid modification to the development of small 
molecule turn mimetics.[1-2, 4] However, these approaches 
often generate overly flexible scaffolds that reduce receptor 
selectivity and potency[5] or require complex synthetic 
strategies.[6] In the absence of precise three-dimensional 
structures of ligands in complex with membrane proteins[7] 
the introduction of conformational constraints (cyclization 
and turn mimetics) is a promising approach to developing 
bioactive peptidomimetics.[8]  Such strategies have produced 
clinically relevant[9] and potent peptidomimetics of 
somatostatin, angiotensin II receptor antagonists, integrin 
inhibitors, and oxytocin and vasopressin analogues.[3] 
To date, there is no design strategy that can generate readily 
accessible diverse sets of turn mimetics with properties 
appropriate for further drug development. Here, we describe 
a broadly applicable combinatorial chemistry approach that 
addresses some of these shortcomings and use it to design a 
norepinephrine reuptake inhibitory peptide mimetic of 
exceptional metabolic stability.  
 
 
 
Scheme 1 A: NMR structure of -conopeptide 1[10] highlighting the 
pharmacophore of this norepinephrine reuptake inhibitor B: 
Pharmacophore (GYKL) of 1 represented by an inverse turn; C: 
Design of N- to C- cyclic vicinal disulfide constrained peptide turn 
mimetic with x indicating the modification sites. 
The -conotoxin MrIa (1) (Scheme 1A: sequence 
NGVCCGYKLCHOC) non-competitively inhibits the 
norephinephrine transporter (NET) and a closely related 
analog Xen2174 (1a) (sequence UGVCCGYKLCHOC where 
U=pyroglutamyl) is currently under development for the 
treatment of severe pain.[10a, 11] These -conotoxins contain 
the sequence GYKL that is essential for high affinity NET 
inhibition.[10a] Structural studies reveal that the rigid 
framework formed by two disulfide bonds between the 
cysteine residues (1-4, 2-3) induces a -hairpin with two anti-
parallel strands (Scheme 1A) connected by an inverse -turn 
comprising GYK,[10b] further constraining the pharmacophore  
(Scheme 1B).  
Our initial design strategy involved incorporating the YKL 
pharmacophore within a cyclic peptide.  To minimize the size 
of the ring and restrict flexibility, we incorporated a vicinal 
disulfide bond as a further constraint (Scheme 1C) and then 
varied the amino acids (Figure 1C indicated as X) adjacent to 
the YKL pharmacophore to modulate structure and gain 
additional structure-activity information. Vicinal disulfide 
bonds are found in the active sites of enzymes,[12] near the 
binding site of receptors[12-13] as well as in toxin peptides.[14] 
In proteins, this unique 8-membered ring prefers a type VIII 
turn with a distorted trans-amide conformation,[12] while in 
small model peptides cis or trans amide bond conformations 
are observed[15] In receptors, vicinal disulfide bonds may 
function as regulatory switches through manipulation of their 
oxidation state.[12, 16]  
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We used intramolecular native chemical ligation (NCL) to 
access these designed turn mimetics. Conveniently, the NCL 
approach[17] allows access to a diverse range of cyclopeptides 
without the need for complex side chain protection strategies.   
To produce cyclic peptide libraries where X is variable 
(Scheme 1C) we employed Boc chemistry to synthesize the 
peptide thioesters necessary for the NCL cyclization. Though 
Boc-chemistry is well established and robust, throughput is 
limited by the final HF cleavage step.[17] To overcome this 
bottleneck we employed the combination of a safety catch 
amide linker and a resin support that is compartmentalized to 
allow easy manual handling and sorting (Scheme 2). 
Starting with Mimotopes aminomethylated lanterns, a safety 
catch linker (SCAL)[18] was attached (2), followed by a Gly 
spacer and a mercaptopropionic acid linker. The thiol resin 
(3) was then used to produce the cyclic peptide libraries 
(Figure 1C) of type 8 (Scheme 2) in a split and mix fashion 
using standard peptide coupling conditions. After chain 
assembly was complete the thioester-loaded lanterns 4 were 
transferred together into a single HF cleavage vessel, which 
allowed removal of the side chain protecting groups, while 
the HF stable SCAL maintains the deprotected thioester on 
resin (4  5). The free thioester peptides 7 are obtained after 
sorting the lanterns into individual vials and addition of 
NH4I/DMS/TFA, which both reduces the SCAL sulfoxide (5 
 6) and renders the substituted benzhydrylamine linkage 
TFA labile, while oxidizing the vicinal disulfide bond to 
yield 7.[18-19] The crude peptide-thioesters 7 were readily N-C 
cyclized in a 0.1 M NH4HCO3 buffer to yield (8), the 
formation of which is autocatalyzed by the thiol released 
from the linker moiety during cyclization (See SI) 
Cyclic peptides 8a-8j were tested on a functional human 
norepinephrine transporter assay. Table 1 show that our 
design strategy successfully generated active mimetics of 
peptide 1, with the vicinally constrained cyclic heptapeptide 
8a (CCGYKLG) equipotent to 1. Other analogs showed that 
we could manipulate potency by varying either the 
pharmacophoric residues or residues at positions X. To 
confirm that the vicinal disulfide bond is a structurally 
essential element for the cyclopeptide bioactivity, we reduced 
peptidomimetic 8a using TCEP and S-alkylated the cysteine 
residues with iodo-acetamide or iodomethane. The cyclic and 
S-alkylated products (9 and 10, Table 1) showed ~ 10-fold 
loss in activity, confirming the importance of the vicinal 
disulfide bond.  
The structure of mimetic 8a in water (with 5% D2O) was 
determined by 1D 1H-NMR and 2D NMR (TOCSY, NOESY, 
1H-13C HSQC) at a 1H frequency of 900 MHz. Structure 
calculations were performed using the torsion angle dynamics 
approach of CYANA v3.0[20] with automated nOe 
assignments. The nOe data was supplemented with backbone 
angle restraints based on 1H and 13C chemical shift data using 
TALOS+.[21] Sufficient nOe interactions enabled 
determination of a high-resolution structure of 8a. (Figure 
3A) The vicinal disulfide bond in 8a results in a distorted 
trans-amide bond (41° from planarity), consistent with 
previous reports[22] (see also SI), which allowed formation of 
a hydrogen bond between Cys1-(CO) and Tyr4-(NH) that 
stabilized the CCGY-region in a -turn conformation (Figure 
3A). Superposition of the YKL side chains of the parent 
compound 1 and the mimetic 8a revealed a high degree of 
overlap, suggesting that the mimetic retained the 
pharmacophore of 1 (RMSD over C atoms: 0.06 Å and 
C  0.22 Å, see Scheme 3B). In contrast, NMR 
analysis of the reduced and methylated 10 produced results 
consistent with a random coil, with no long range interactions, 
confirming that the vicinal disulfide bond provided a key 
structural constraint (SI). 
 
Scheme 2:  High throughput synthesis of peptide thioester (7) and intramolecular native chemical ligation, yielding cyclic peptide turn 
mimetics (8): A combination of a safety catch linker / thiol linker (2  3) together with compartmentalized resin (lanterns) allows for split and 
mix Boc-synthesis (3  4) and parallel hydrogen fluoride deprotection ( 5). After sorting and safety catch linker activation (5  6) peptide 
thioester 7 is obtained. Native chemical ligation yields cyclic peptides of type 8 
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Table 1: Norepinephrine reuptake inhibition (IC50  SEM) of vicinal 
disulfide constrained cyclic peptidomimetics (8a–8j), and -
conopeptides 1 (1-4, 2-3 disulfide bond). Reduced and alkylated 
products 9, and 10 show decreased activity due to loss of the vicinal 
disulfide constraint. 
Entry Sequence IC50  [M] 
1 NGVCCGYKLCHOC[a] 2.45 ± 0.07 
1a UGVCCGYKLCHOC[a] 2.55 ± 0.18 
8a (CCGYKLG) 3.9 ± 0.2 
8b (CCGYK[CHA]G)[b] 2.3 ± 0.3 
8c (CCGYKL-) 31.6 ± 4 
8d (CCGYK[CHA]-)[b] 18 ± 1.2 
8e (CCEYKLG) 117 ± 2.8 
8f (CCFYKLG) 72 ± 6 
8g (CCH(Dnp)YKLG)[c] 24 ± 11 
8h (CCLYKLG) 63 ± 20 
8i (CCWYKLG) 28 ± 11 
8j (CCFYKL-) 87 ± 14 
9 ([C-Saa][C-Saa]GYKLG)[d] 20 ± 3 
10 ([C-SMe][C-SMe]GYKLG)[e] 49 ± 8 
[a] (U = pyroglutamic acid, O = hydroxyproline), [b] CHA = cyclohexyl 
alanine [c] Dnp = 2,5-dinitrophenyl, [d] Saa = S-acetamidated cysteine 
(= S-CH2CONH2), 
[e] SMe = S-methylated cysteine 
We further evaluated the suitability of analogues 8a and 
8b as clinical leads. Unlike many peptides, we found that 
peptidomimetic 8a which is stable in trypsin (SI) and both 8a 
and 8b had exceptional stability in plasma that was not 
derived from serum albumin adsorption (SI) and remained 
predominantly intact for at least 50 h (Scheme 4). This 
stability can be attributed to the N to C cyclization[23] but the 
stability of the disulfide bond (redox potential of 8a -313mV 
see SI), which forms readily even under highly acidic 
conditions, may also contribute. This redox potential of 8a 
compared well with values reported for similar transoid 
vicinal disulfides[15] and is surprisingly more stable than 
many natural occurring disulfides.[24] We also established (SI) 
that the mimetic 8a inhibits NET in isolated rat brain slices 
(IC50 = 4.2 µM), indicating its stability not only in plasma but 
also in brain tissue. 
In conclusion, this work describes the synthesis of 
peptide turn mimetics that combines a novel high throughput 
combinatorial strategy for peptide thioesters and their 
subsequent conversion into backbone cyclic peptides 
containing a vicinal disulfide constraint. Our results 
demonstrate that it is possible to graft an active peptide turn 
onto a vicinal disulfide constrained cyclic scaffold to both 
improve chemical and biological stability while maintaining 
full potency. Although this work is based on a well 
characterized peptide turn[10a], we believe that this approach 
can be broadly applied to the design of other turn mimetics 
where such knowledge is unavailable. This is due to the fact 
that the topological orientation of pharmacophore side chains 
largely determines bioactivity rather then the specific turn 
type.[25] 
 
Scheme 3 A: NMR structure of vicinal disulfide constrained cyclic 
peptidomimetics 8a. B: superposition of the pharmacophore region of 
-conopeptide (1, grey) with the mimetic 8a (red). 
 
Scheme 4: Plasma stability of cyclic peptidomimetics 8a and 8b 
compared to clinical candidate 1a. 
Experimental Section 
Experimental details are described in the Supporting 
Information.  
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Vicinal disulfide constrained 
cyclic peptidomimetics: a turn 
mimetic scaffold targeting the 
norepinephrine transporter  
 
Peptide turn mimetic development of a clinically relevant norepinephrine reuptake 
inhibitor is presented employing a high throughput synthesis approach to generate 
peptide thioesters with subsequent cyclization via native chemical ligation. The 
vicinal disulfide constrained cyclic peptidomimetics show high structural and 
functional similarity to the parent peptide though with superior metabolic stability. 
 
 
 
